

PRODUCT INFORMATION



Cdk1/2 Inhibitor III

Item No. 18859

CAS Registry No.: 443798-47-8
Formal Name: 5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide

Synonym: Cyclin-dependent kinase 1/2 Inhibitor III

MF: C₁₅H₁₃F₂N₇O₂S₂

FW: 425.4


Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years

Special Conditions: Protect from light



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cdk1/2 Inhibitor III is supplied as a solid. A stock solution may be made by dissolving the Cdk1/2 inhibitor III in the solvent of choice. Cdk1/2 Inhibitor III is soluble in the organic solvent DMSO, which should be purged with an inert gas. The solubility of Cdk1/2 inhibitor III in DMSO is approximately 10 mg/ml. Cdk1/2 Inhibitor III is also soluble in acetone and tetrahydrofuran.

Cdk1/2 Inhibitor III is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Cyclin-dependent kinases (Cdks) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.¹ Cdk1/2 Inhibitor III is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A (IC₅₀s = 0.6 and 0.5 nM, respectively).² It less potently inhibits CDC2-like kinases 1 and 3, VEGFR2, and GSK-3β (IC₅₀s = 8.9, 29, 32, and 140 nM, respectively) and is without effect against a panel of other kinases.^{2,3} Cdk1/2 Inhibitor III blocks the growth of several cancer cell lines (IC₅₀ values range from 20 to 92 nM).²

References

1. Bettayeb, K., Baunbaek, D., Delehouze, C., *et al.* CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. *Genes Cancer* **1**(4), 369-380 (2010).
2. Lin, R., Connolly, P.J., Huang, S., *et al.* 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities. *J. Med. Chem.* **48**(13), 4208-4211 (2005).
3. Fedorov, O., Huber, K., Eisenreich, A., *et al.* Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. *Chem. Biol.* **18**(1), 67-76 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/14/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM